Management of Borderline Common Bile Duct Stone (CBDS)
Common Bile Duct Stone
About this trial
This is an interventional treatment trial for Common Bile Duct Stone
Eligibility Criteria
Inclusion Criteria:
Inclusion criteria:
- CBD diameter less than 10mm.
- Single or 2 stones in number.
- Size of stone 5mm or less.
- Serum bilirubin level less than 10 mg/dl .
- SGPT, SGOT less than 300.
- Associated gallbladder stones
Exclusion Criteria:
- Previous cholecystectomy.
- History of acute cholecystitis, pancreatitis, or cholangitis.
- Previous history of endoscopic sphincterotomy.
- Unfit patients for cholecystectomy.
- No gallbladder stones.
- Patients with altered GIT anatomy.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
conservative
ERCP (endoscopic)
1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones. Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days. No improvement: the patient will undergo ERCP and then LC.
2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days. b- No improvement: the patient will undergo ERCP and then LC.